CFTR and cystic fibrosis: Earlier reports revealed the potential benefits of using mAbs for diagnosis of CF, correction of specific CFTR mutations, and development of mAbs against Pseudomonas aeruginosa (P. aeruginosa), the most common pathogen found in the lungs of CF patients (Coutinho et al., 2008, Lovato et al., 2007).